🇺🇸 FDA
Pipeline program

PTG-100

PTG-100-02

Phase 2 small_molecule terminated

Quick answer

PTG-100 for Ulcerative Colitis is a Phase 2 program (small_molecule) at Protagonist Therapeutics, Inc with 1 ClinicalTrials.gov record(s).

Program details

Company
Protagonist Therapeutics, Inc
Indication
Ulcerative Colitis
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials